CY1111815T1 - Κυκλικοι πεπτιδικοι antαγωνιστες toy cxcr4 - Google Patents

Κυκλικοι πεπτιδικοι antαγωνιστες toy cxcr4

Info

Publication number
CY1111815T1
CY1111815T1 CY20111100861T CY111100861T CY1111815T1 CY 1111815 T1 CY1111815 T1 CY 1111815T1 CY 20111100861 T CY20111100861 T CY 20111100861T CY 111100861 T CY111100861 T CY 111100861T CY 1111815 T1 CY1111815 T1 CY 1111815T1
Authority
CY
Cyprus
Prior art keywords
cxcr4
toy
cyclic peptide
peptide antagonists
antagonists
Prior art date
Application number
CY20111100861T
Other languages
English (en)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111815(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1111815T1 publication Critical patent/CY1111815T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Παρέχονται κυκλοποιημένοι μέσω λακτάμης πεπτιδικοί ανταγωνιστές του CXCR4 χρήσιμοι στην θεραπευτική αγωγή καρκίνων, ρευματοειδούς αρθρίτιδας, πνευμονικής ίνωσης, και λοίμωξης HIV.
CY20111100861T 2007-05-30 2011-09-07 Κυκλικοι πεπτιδικοι antαγωνιστες toy cxcr4 CY1111815T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
EP08769524A EP2160221B1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Publications (1)

Publication Number Publication Date
CY1111815T1 true CY1111815T1 (el) 2015-10-07

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100861T CY1111815T1 (el) 2007-05-30 2011-09-07 Κυκλικοι πεπτιδικοι antαγωνιστες toy cxcr4

Country Status (33)

Country Link
US (3) US7691813B2 (el)
EP (2) EP2160221B1 (el)
JP (1) JP5358564B2 (el)
KR (2) KR101169846B1 (el)
CN (1) CN101678213B (el)
AR (1) AR066648A1 (el)
AT (1) ATE516853T1 (el)
AU (1) AU2008260326B2 (el)
BR (1) BRPI0812134A2 (el)
CA (1) CA2688574C (el)
CL (1) CL2008001467A1 (el)
CO (1) CO6241137A2 (el)
CR (1) CR11105A (el)
CY (1) CY1111815T1 (el)
DK (1) DK2160221T3 (el)
DO (1) DOP2009000270A (el)
EA (1) EA017716B1 (el)
GT (1) GT200900304A (el)
HK (1) HK1141474A1 (el)
HR (1) HRP20110551T1 (el)
IL (1) IL201685A (el)
JO (1) JO2776B1 (el)
MA (1) MA31666B1 (el)
MX (1) MX2009012952A (el)
MY (1) MY149432A (el)
NZ (1) NZ580849A (el)
PE (1) PE20090299A1 (el)
PL (1) PL2160221T3 (el)
PT (1) PT2160221E (el)
TN (1) TN2009000496A1 (el)
TW (1) TWI423987B (el)
WO (1) WO2008150689A1 (el)
ZA (1) ZA200908345B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
US9079939B2 (en) * 2011-06-07 2015-07-14 Polyphor Ag Beta-hairpin peptidomimetics as CXC4 antagonists
CN104780930A (zh) * 2011-09-30 2015-07-15 程云 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
EP3613435A1 (en) 2015-01-28 2020-02-26 Universite De Bordeaux Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CA3032885C (en) * 2016-09-06 2023-06-20 Mainline Biosciences Cxcr4 antagonists and methods of use
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
CN111183146A (zh) * 2017-09-05 2020-05-19 主线生物科学公司 高亲和力选择性结合cxcr4的缀合物及其使用方法
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US11639373B2 (en) 2018-09-12 2023-05-02 Technische Universität München Therapeutic and diagnostic agents for cancer
AU2019338221B2 (en) 2018-09-12 2024-04-04 Technische Universität München CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity
CN114364690A (zh) * 2019-04-18 2022-04-15 省卫生服务机构 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
EP4269422A1 (en) * 2020-12-25 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
WO2023201435A1 (en) * 2022-04-20 2023-10-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
EP1991562A2 (en) * 2006-02-27 2008-11-19 Technische Universität München Cancer imaging and treatment

Also Published As

Publication number Publication date
CA2688574C (en) 2014-02-18
KR20100003737A (ko) 2010-01-11
IL201685A0 (en) 2010-05-31
KR101319740B1 (ko) 2013-10-17
HK1141474A1 (en) 2010-11-12
CN101678213B (zh) 2013-11-06
PT2160221E (pt) 2011-09-12
CL2008001467A1 (es) 2008-12-05
JP2010529957A (ja) 2010-09-02
AU2008260326B2 (en) 2011-07-21
DK2160221T3 (da) 2011-09-19
CR11105A (es) 2010-04-12
EP2160221B1 (en) 2011-07-20
USRE42274E1 (en) 2011-04-05
EP2160221A1 (en) 2010-03-10
NZ580849A (en) 2012-03-30
TN2009000496A1 (en) 2011-03-31
PL2160221T3 (pl) 2011-12-30
TW200902556A (en) 2009-01-16
US20080300177A1 (en) 2008-12-04
US7691813B2 (en) 2010-04-06
EA200971129A1 (ru) 2010-04-30
AR066648A1 (es) 2009-09-02
KR101169846B1 (ko) 2012-08-01
PE20090299A1 (es) 2009-03-19
BRPI0812134A2 (pt) 2014-11-18
MA31666B1 (fr) 2010-09-01
HRP20110551T1 (hr) 2011-09-30
JP5358564B2 (ja) 2013-12-04
MX2009012952A (es) 2009-12-11
WO2008150689A1 (en) 2008-12-11
GT200900304A (es) 2011-11-09
CA2688574A1 (en) 2008-12-11
JO2776B1 (en) 2014-03-15
TWI423987B (zh) 2014-01-21
IL201685A (en) 2015-04-30
DOP2009000270A (es) 2010-01-15
EP2377579A1 (en) 2011-10-19
MY149432A (en) 2013-08-30
AU2008260326A1 (en) 2008-12-11
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
ATE516853T1 (de) 2011-08-15
EA017716B1 (ru) 2013-02-28
US20100130409A1 (en) 2010-05-27
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23

Similar Documents

Publication Publication Date Title
CY1111815T1 (el) Κυκλικοι πεπτιδικοι antαγωνιστες toy cxcr4
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
CY1118279T1 (el) Φαρμακευτικeς συνθeσεις
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
CY1110170T1 (el) Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
DK1543063T3 (da) Medikament levering
DE602005019439D1 (de) Biologisch abbaubare kationische polymere
CY1109914T1 (el) Μαλακες καψουλες που περιλαμβανουν υδροχλωρικη πανολοσετρονη και εχουν βελτιωμενη σταθεροτητα και βιοδιαθεσιμοτητα
NO20082531L (no) Neuropilinantagonister
WO2006092722A8 (en) Peptidomimetic compounds and preparation of biologically active derivatives
MX2015012119A (es) Poliamidas con funcionalidad amina.
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
NO20081574L (no) Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom
CY1113770T1 (el) Κυκλικα αντι-μικροβιακα πεπτιδια
CY1107254T1 (el) Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
ATE533517T1 (de) Biologisch abbaubare polyphosphazene mit pyrrolidonseitengruppen
EA200401331A1 (ru) Фармацевтическая препаративная форма, включающая мелатонин